山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (11): 48-52.doi: 10.6040/j.issn.1671-7554.0.2021.0795
梁婷婷,杨勇霞,侯丛哲,黄太胜,王华丽,朱琳
LIANG Tingting, YANG Yongxia, HOU Congzhe, HUANG Taisheng, WANG Huali, ZHU Lin
摘要: 目的 分析397例患者中PAX1基因甲基化与宫颈高级别上皮内病变及高危型人乳头瘤病毒(HR-HPV)分型的关联性。 方法 2019年8月至2020年10月于山东大学第二医院行宫颈薄层液基细胞学检查(TCT)和HR-HPV DNA检查的女性中,选取TCT结果异常:≥意义不明的非典型鳞状细胞(ASCUS)和/或HR-HPV阳性的患者397例;根据2020年阴道镜应用的中国专家共识,转诊阴道镜,阴道镜检查结果异常者行定点活检病理检查;RT-qPCR检测患者的PAX1甲基化程度。 结果 病理分级为宫颈上皮内瘤变3级和宫颈癌(CIN3+)(55例)与正常/宫颈炎(72例)、CIN1(36例)、CIN2(72例)患者比较,PAX1甲基化水平分别为18.64(4.01, 20.83)和20.22(19.24, 20.84)、20.33(19.65, 21.00)、20.43(15.31, 21.08),CIN3+患者PAX1甲基化程度高于正常/CIN1/CIN2的患者,差异有统计学意义(Z值分别为3.03、2.65、3.06;P值分别为0.002、0.008、0.002);HPV16阳性患者(89例)与12型高危型HPV(12HR-HPV)阳性的患者(174例)比较,PAX1甲基化水平分别为19.72(10.00, 20.91)和21.00(18.97, 21.02),前者PAX1甲基化程度高于后者,差异有统计学意义(Z=2.736,P=0.006);TCT诊断为ASCUS的患者, 病理分级CIN2+(23例)与正常/CIN1(19例)比较,PAX1甲基化水平分别为20.47(19.33, 21.18)和18.03(11.2, 20.82),前者PAX1甲基化程度高于后者,差异有统计学意义(Z=2.45, P=0.014)。 结论 PAX1甲基化程度与宫颈高级别上皮内病变及感染的HPV型别有关联,PAX1甲基化检测有助于早期识别CIN3+及ASCUS中的宫颈高级别病变,帮助ASCUS的分流、减少阴道镜的转诊率。
中图分类号:
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. [2] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application [J]. Nat Rev Cancer, 2002, 2(5): 342-350. [3] MacLaughlin KL, Jacobson RM, Radecki BC, et al. Trends over time in pap and pap-HPV cotesting for cervical cancer screening[J]. J Womens Health(Larchmt). 2019,28(2):244-249. [4] Nkwabong E, Laure Bessi Badjan I, Sando Z.Pap smear accuracy for the diagnosis of cervical precancerous lesions [J]. Trop Doct, 2019, 49(1): 34-39. [5] Narkcham S, Mody DR, Jones A, et al. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping [J]. J Am Soc Cytopathol, 2021, 19: S2213-2945. doi: 10.1016/j.jasc.2021.05.002. [6] Er Güneri S, ?瘙塁en S. Womens experiences after abnormal Pap smear results: a qualitative study [J]. J Psychosom Obstet Gynaecol, 2020, 41(1): 22-29. [7] Hoda RS, Finer EB, Arpin RN, et al. Risk of malignancy in the categories of the Papanicolaou Society of Cytopathology system for reporting pancreaticobiliary cytology [J]. J Am Soc Cytopathol, 2019, 8(3): 120-127. [8] Bhatla N, Singhal S. Primary HPV screening for cervical cancer [J]. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 98-108. doi: 10.1016/j.bpobgyn.2020.02.008. [9] Pista A, Costa C, Saldanha C, et al. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies [J]. BMC Public Health, 2019, 19(1): 235. doi: 10.1186/s12889-019-6536-4. [10] Zhang Y, Wang J, Zhang R, et al. Application value of detection of high-risk HPV infection in early cervical cancer patients in disease diagnosis and prognosis evaluation [J]. Clin Lab, 2020, 66(12). doi: 10.7754/Clin.Lab.2020.200245. [11] Pruski D, Millert-Kalinska S, Lewek A, et al. Sensitivity and specificity of HR HPV E6/E7 mRNA test in detecting cervical squamous intraepithelial lesion and cervical cancer [J]. BMC Cancer, 2019, 90(2):66-71. [12] Xu G, Liu Y, Zhang C, et al. Temporal and spatial expression of Sox9, Pax1, TGF-β1 and type Ⅰ and Ⅱ collagen in human intervertebral disc development [J]. Neurochirurgie, 2020, 66(3): 168-173. [13] El Aliani A, El-Abid H, El Mallali Y, et al. Association between gene promoter methylation and cervical cancer development: global distribution and a meta-analysis [J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(3): 450-459. [14] Kelly H, Benavente Y, Pavon MA, et al. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia(CIN2+): a systematic review and meta-analysis [J]. Bri J Cancer, 2019, 121(11): 954-965. [15] Fang C, Wang SY, Liou YL, et al. The promising role of PAX1(aliases: HUP48, OFC2)gene methylation in cancer screening [J]. Mol Genet Genomic Med, 2019, 7(3): e506. doi: 10.1002/mgg3.506. [16] 李明珠, 魏丽惠. 甲基化检测在宫颈癌诊治中的意义[J].现代妇产科进展,2019, 28(9): 704-705. LI Mingzhu, WEI Lihui. Significance of methylation detection in the diagnosis and treatment of cervical cancer [J]. Progress in Obstetrics and Gynecology, 2019, 28(9): 704-705. [17] Li B, Guo R, Lai T, et al. The application of PAX1 methylation detection and HPV E6/E7 mRNA detection in cervical cancer screening [J]. J Obstet Gynaecol Res, 2021, 47(8): 2720-2728. [18] Dvorská D, Brany D, Nagy B, et al. Aberrant methylation status of tumour suppressor genes in ovarian cancer tissue and paired plasma samples [J]. Int J Mol Sci, 2019, 20(17): 4119. doi: 10.3390/ijms20174119. [19] Liu H, Meng X, Wang J. Real time quantitative methylation detection of PAX1 gene in cervical cancer screening [J]. Int J Gynecol Cancer, 2020, 30(10): 1488-1492. [20] Wang M, Hou B, Wang X, et al. Diagnostic value of high-risk human papillomavirus viral load on cervical lesion assessment and ASCUS triage [J]. Cancer Med, 2021, 10(7): 2482-2488. [21] Oranratanaphan S, Kobwitaya K, Termrungruanglert W, et al. Value of CCNA1 promoter methylation in triaging ASC-US cytology [J]. Asian Pac J Cancer Prev, 2020, 21(2): 473-477. [22] Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: us preventive services task force recommendation statement [J]. JAMA, 2018, 320(7): 674-686. [23] Sammarco ML, Tamburro M, Pulliero A, et al. Human papillomavirus infections, cervical cancer and microRNAs: an overview and implications for public health [J]. Microrna, 2020, 9(3): 174-186. [24] Gutnik H, Kastelic P, Otrbenk Valen cak A, et al. Histomorphologic assessment and distribution of high-risk human papillomavirus(HPV)types in cervical high-grade squamous intraepithelial lesions with unusual histomorphologic features [J]. Virchows Arch, 2020, 476(2): 251-260. [25] Torres-Poveda K, Ruiz-Fraga I, Madrid-Marina V, et al. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program [J]. BMC Cancer, 2019, 19(1): 1205. doi: 10.1186/s12885-019-6388-4. [26] 王文杰, 余敏红, 范世珍, 等. 人乳头瘤病毒(HPV)型别与SOX1和PAX1基因甲基化的相关性研究[J]. 中国实验诊断学, 2020, 24(8): 1353-1356. WANG Wenjie, YU Minhong, FAN Shizhen, et al. A correlation between human papillomavirus(HPV)type and methylation of SOX1 and PAX1 genes [J]. Chinese Journal Laboratory Diagnosis, 2020, 4(8): 1353-1356. |
[1] | 修德健,高正文,宋婷婷,崔楠,崔静,孙健平. 生物信息学方法分析与宫颈癌有关联的基因[J]. 山东大学学报 (医学版), 2022, 60(10): 99-109. |
[2] | 陈泉材,韩赛,刘露,孙雨,尤学武,张俊华,张友忠. CDC7、MCM4在105例宫颈病变组织中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(1): 34-39. |
[3] | 王璐,赵新蕊,朱琳. 25例早期宫颈癌无瘤化免举宫腹腔镜子宫切除术临床效果[J]. 山东大学学报 (医学版), 2021, 59(6): 76-80. |
[4] | 杨佳欣,沈铿,王遥. 妇科恶性肿瘤保留生育功能治疗的现状与展望[J]. 山东大学学报 (医学版), 2018, 56(5): 1-7. |
[5] | 陈颖,周小青,齐眉,张魏芳,刘娟,赵蔚明. 干扰PRPS2基因表达对宫颈癌细胞生物学特性的影响[J]. 山东大学学报 (医学版), 2018, 56(2): 9-13. |
[6] | 王永,姜晨,周士英,杨晓玫. IQ结构域GTP酶激活蛋白3表达对宫颈癌细胞增殖和转移的影响[J]. 山东大学学报 (医学版), 2018, 56(10): 103-109. |
[7] | 丁长宽,陈健行. 蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2018, 56(1): 70-75. |
[8] | 刘京康,杨建勇,孟丽华,姜洁. 血清miR-17-92簇在HPV阳性宫颈癌中的早期诊断价值[J]. 山东大学学报(医学版), 2017, 55(5): 86-90. |
[9] | 孙泽雨,陈颖,林家香,刘娟,赵蔚明. 磷脂酰肌醇-4-磷酸酶II型对宫颈癌细胞增殖及凋亡的影响[J]. 山东大学学报(医学版), 2017, 55(11): 1-6. |
[10] | 王雅芬,杨勇霞,刘娅,马德美,朱琳. 宫颈细胞学阴性且高危型人乳头瘤病毒阳性人群的分流方法[J]. 山东大学学报(医学版), 2016, 54(8): 69-71. |
[11] | 彭慧,何君梅,苏雪莲. 血清循环miR-375检测对宫颈癌早期诊断及术后监测的意义[J]. 山东大学学报(医学版), 2016, 54(3): 68-71. |
[12] | 杜义江, 肖长义, 叶红, 汤桂成, 黎家华. CaSki细胞内HPVL1蛋白的表达[J]. 山东大学学报(医学版), 2015, 53(3): 17-21. |
[13] | 冯建丽, 董淑云. 宫颈癌根治术后淋巴囊肿的护理[J]. 山东大学学报(医学版), 2014, 52(S2): 141-141. |
[14] | 李贺群, 聂春兰. 宫颈癌合并肺肾转移1例[J]. 山东大学学报(医学版), 2014, 52(S1): 119-119. |
[15] | 袁首道, 王凤琴, 张娇, 赵蔚明, 陈健行. 宫颈腺癌细胞与宫颈鳞癌细胞蛋白表达差异的质谱分析[J]. 山东大学学报(医学版), 2014, 52(8): 14-21. |
|